title: Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
authors.forename: Katrin Baumann
authors.initials: KB
authors.lastname: Conzett
authors.forename: Isabel
authors.initials: I
authors.lastname: Kolm
authors.forename: Ilijas
authors.initials: I
authors.lastname: Jelcic
authors.forename: Jivko
authors.initials: J
authors.lastname: Kamarachev
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.forename: Ralph
authors.initials: R
authors.lastname: Braun
authors.forename: Lars E
authors.initials: LE
authors.lastname: French
authors.forename: Michael
authors.initials: M
authors.lastname: Linnebank
authors.forename: Günther F L
authors.initials: GF
authors.lastname: Hofbauer
mesh_terms: D000328:Adult; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008545:Melanoma / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000139:chemically induced*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine